-
HOME
- news
-
PR
Tamibarotene Designated as an Orphan Drug for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
PR
Rege Nephro Co., Ltd. Selected for the Incubator Program “Bayer Co.Lab Connect”
-
PR
Akifumi Morinaka, Chief Executive Officer, Receives an Award at the “2nd ‘Young People Creating the Future’ Startup Pitch Kansai”
-
PR
Professor Kenji Osafune, Chief Scientific Advisor, Presents at the 2025 Taiwan Regenerative Medicine Summit
-
PR
Rege Nephro Co., Ltd. Signs Collaborative Research Agreement with Fujifilm for the Development of a Human Kidney Chip
-
PR
The research group of Professor Kenji Osafune, Chief Scientific Advisor, has confirmed cell therapy efficacy in mouse model on chronic kidney disease (CKD) and published a research paper about the achievement
-
PR
Professor Kenji Osafune, Chief Scientific Advisor, Receives Award from the Japanese Society for Regenerative Medicine
-
PR
Akifumi Morinaka, Chief Executive Officer, Speaks at ‘JHVS Symposium for Medical Ventures and Academia’
-
PR
Akifumi Morinaka, Chief Executive Officer, Presented at Healthcare Conference Taipei 2025
-
PR
Rege Nephro Co., Ltd. Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals, Inc.
-
PR
Rege Nephro Co., Ltd. and Roche Enter into Collaborative Research Agreement on iPSC-Derived Human Disease Models
-
PR
Professor Kenji Osafune, Chief Scientific Advisor, ran the Osaka Marathon 2025
-
PR
Patient Enrollment for Phase II clinical trial for Tamibarotene for ADPKD has been completed
-
PR
Professor Osafune, Chief Scientific Advisor, to deliver a Lecture at THE 9TH ACADEMIC GOVERNMENT SYMPOSIUM ON REGENERATIVE MEDICINE
-
PR
Rege Nephro featured as One of the Companies in “7 Japanese Startups to Watch in 2025”
-
PR
Professor Osafune, Chief Scientific Advisor, Awarded The 12th CiRA Award
-
PR
Rege Nephro awarded as a 2024 KSII Zebra by Kansai Innovation Initiative
-
PR
Professor Osafune, Chief Scientific Advisor, gave an invited lecture at the 2nd National Taiwan University and Kyoto University Joint-symposium
-
PR
Miwa Yoshida to Speak at “Business Development Seminar for Early-Stage Startups in the Bio-Life Sciences Field” on January 27th, 2025
-
PR
Presented at the AMED Seeds Acceleration Pitch and JHVS Venture Awards 2024 at the Japan Healthcare Venture Summit (JHVS) 2024.
-
PR
Professor Kenji Osafune, Chief Scientific Advisor gave lectures in Taiwan
-
PR
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
-
Media
Upcoming Feature on NHK World JAPAN Science View: Freeing Patients from Dialysis! -Dr. Kenji OSAFUNE’s Challenge
-
PR
Rege Nephro’s Chief Executive Officer gave a lecture at Regenerative Medicine Expo[Tokyo].
-
PR
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
-
PR
Phase II clinical trial begins for polycystic kidney disease drug candidate identified by iPS cell-based drug discovery
-
PR
Rege Nephro exhibited at “JAPAN KYOTO TRADE EXIBITION 2024” held in Dubai, UAE
-
PR
Rege Nephro exhibited at “InnoVision from Kyoto University: Seeing the Future through Innovation” held in Singapore
-
PR
A research group of Senior Researcher Hiraku Tsujimoto and Professor Kenji Osafune have developed a selective induction method of renal interstitial progenitor cells from human iPS cells and successfully created kidney tissues with glomerular mesangium structures, and published a research paper about that...
-
PR
Rege Nephro announces joint research agreement with CiRA Kyoto University and Abu Dhabi Stem Cells Center Aiming to develop new treatments for diabetes through collaborative research using iPS cells
-
PR
Professor Kenji Osafune, our scientific founder, gave lectures in Taiwan
-
PR
Rege Nephro Announces Joint Research Agreement with CiRA-Kyoto University, Toyo Seikan Group Holdings, and Shimadzu Corporation Aiming to develop novel cell therapy that suppresses the progression of liver cirrhosis
-
PR
Rege Nephro announces extension of joint research agreement with CiRA-Kyoto University and AstraZeneca Aiming to realize kidney regenerative medicine with a strong international team
-
PR
Professor Kenji Osafune gave a lecture in “ADSCC CONGRESS 2023” held in Abu Dhabi, UAE
-
PR
Rege Nephro will soon begin a clinical trial for autosomal dominant polycystic kidney disease (ADPKD) discovered by our scientific founder, Professor Kenji Osafune.
-
PR
A research group of Professor Kenji Osafune has identified a drug candidate for the treatment of autosomal dominant polycystic kidney disease (ADPKD) and published a research paper about that achievement
-
PR
Announcement for Fund raising
-
PR
Appointment of Representative Director
-
PR
Selected as a J-Startup, a public-private startup support program
-
PR
Development of a method to confirm that no undifferentiated cells remain in renal progenitor cells generated from human iPS cells
-
PR
Rege Nephro Announces Joint Research Agreement with CiRA, Kyoto University and Mitsui Chemicals Aiming to develop exosomes as a new modality (therapeutic method)
-
Media
Our business was introduced in Science Japan, an online magazine published by JST.
-
PR
Rege Nephro Announces Joint Research Agreement with CiRA, Kyoto University and AstraZeneca Research aims to produce kidney tissue from induced pluripotent stem cells
-
PR
Notice of Series A capital increase through third-party allotment of shares
-
PR
Notice that Katsuhisa Yamaguchi, CFO and General Manager of Finance & Administration, has been appointed as a member of the board of directors
-
PR
Toward development of cell therapy for renal diseases using iPS cells Joint research on the development of monitoring methods for the quality and manufacturing processes of nephron progenitor cells
-
PR
Notice of Relocation
-
PR
Current status and future directions of clinical applications using iPS cells – focus on Japan
-
PR
An article about Toshihiro Ishikiriyama, our president, and Kenji Osafune, our Chief Scientific Advisor , was published in serial column: Series EMBARK of K-iCAP.
-
PR
Shunjiro Sugimoto has expired his term of office of the board director, resigned general manager of the production division and became an advisor.
-
Media
An article about Toshihiro Ishikiriyama, our president, was published in AnswersNews, serial column: Venture Round Visit Report.
-
PR
The current status and future perspectives of iPSC technology-based regenerative medicine for kidney diseases.
-
PR
Elucidation of mechanism of the production of erythropoietin for the development of new therapeutic agents for renal anemia
-
PR
A review article on the development of regenerative medicines for renal diseases
-
PR
A review article on the kidney organoids generated from iPS cells and their clinical applications
-
PR
Notice of joint research agreement with ABI CO., LTD.
-
PR
Notice of joint research agreement with NIKKISO CO., LTD.
-
PR
Notice of Conclusion of Joint Research Agreement with Kirin Holdings Co., Ltd.
-
PR
Succeeded in producing a large amount of tissue that is the basis of renal collecting duct
-
Media
Featured in Nikkei newspaper, its electronic version, Asahi Shimbun DIGITAL and many other media.
-
PR
Announcement of financing and business alliance
-
PR
Regenerate renal tissue from multiple renal progenitor cells differentiated from human iPS cells separately
-
PR
Immobilization of low molecular weight compounds that replace BMP7 in the expansion method of renal progenitor cells
-
PR
The company name has been changed from RegeNephron Co., Ltd. to Rege Nephro Co., Ltd.
-
PR
Rege Nephron Co., Ltd. was established.
-
Media
Published in the Nikkei newspaper and the electronic version.
-
Tamibarotene Designated as an Orphan Drug for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
Rege Nephro Co., Ltd. Selected for the Incubator Program “Bayer Co.Lab Connect”
-
Akifumi Morinaka, Chief Executive Officer, Receives an Award at the “2nd ‘Young People Creating the Future’ Startup Pitch Kansai”
-
Professor Kenji Osafune, Chief Scientific Advisor, Presents at the 2025 Taiwan Regenerative Medicine Summit
-
Rege Nephro Co., Ltd. Signs Collaborative Research Agreement with Fujifilm for the Development of a Human Kidney Chip
-
The research group of Professor Kenji Osafune, Chief Scientific Advisor, has confirmed cell therapy efficacy in mouse model on chronic kidney disease (CKD) and published a research paper about the achievement
-
Professor Kenji Osafune, Chief Scientific Advisor, Receives Award from the Japanese Society for Regenerative Medicine
-
Akifumi Morinaka, Chief Executive Officer, Speaks at ‘JHVS Symposium for Medical Ventures and Academia’
-
Akifumi Morinaka, Chief Executive Officer, Presented at Healthcare Conference Taipei 2025
-
Rege Nephro Co., Ltd. Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals, Inc.
-
Rege Nephro Co., Ltd. and Roche Enter into Collaborative Research Agreement on iPSC-Derived Human Disease Models
-
Professor Kenji Osafune, Chief Scientific Advisor, ran the Osaka Marathon 2025
-
Patient Enrollment for Phase II clinical trial for Tamibarotene for ADPKD has been completed
-
Professor Osafune, Chief Scientific Advisor, to deliver a Lecture at THE 9TH ACADEMIC GOVERNMENT SYMPOSIUM ON REGENERATIVE MEDICINE
-
Rege Nephro featured as One of the Companies in “7 Japanese Startups to Watch in 2025”
-
Professor Osafune, Chief Scientific Advisor, Awarded The 12th CiRA Award
-
Rege Nephro awarded as a 2024 KSII Zebra by Kansai Innovation Initiative
-
Professor Osafune, Chief Scientific Advisor, gave an invited lecture at the 2nd National Taiwan University and Kyoto University Joint-symposium
-
Miwa Yoshida to Speak at “Business Development Seminar for Early-Stage Startups in the Bio-Life Sciences Field” on January 27th, 2025
-
Presented at the AMED Seeds Acceleration Pitch and JHVS Venture Awards 2024 at the Japan Healthcare Venture Summit (JHVS) 2024.
-
Professor Kenji Osafune, Chief Scientific Advisor gave lectures in Taiwan
-
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
-
Rege Nephro’s Chief Executive Officer gave a lecture at Regenerative Medicine Expo[Tokyo].
-
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
-
Phase II clinical trial begins for polycystic kidney disease drug candidate identified by iPS cell-based drug discovery
-
Rege Nephro exhibited at “JAPAN KYOTO TRADE EXIBITION 2024” held in Dubai, UAE
-
Rege Nephro exhibited at “InnoVision from Kyoto University: Seeing the Future through Innovation” held in Singapore
-
A research group of Senior Researcher Hiraku Tsujimoto and Professor Kenji Osafune have developed a selective induction method of renal interstitial progenitor cells from human iPS cells and successfully created kidney tissues with glomerular mesangium structures, and published a research paper about that...
-
Rege Nephro announces joint research agreement with CiRA Kyoto University and Abu Dhabi Stem Cells Center Aiming to develop new treatments for diabetes through collaborative research using iPS cells
-
Professor Kenji Osafune, our scientific founder, gave lectures in Taiwan
-
Rege Nephro Announces Joint Research Agreement with CiRA-Kyoto University, Toyo Seikan Group Holdings, and Shimadzu Corporation Aiming to develop novel cell therapy that suppresses the progression of liver cirrhosis
-
Rege Nephro announces extension of joint research agreement with CiRA-Kyoto University and AstraZeneca Aiming to realize kidney regenerative medicine with a strong international team
-
Professor Kenji Osafune gave a lecture in “ADSCC CONGRESS 2023” held in Abu Dhabi, UAE
-
Rege Nephro will soon begin a clinical trial for autosomal dominant polycystic kidney disease (ADPKD) discovered by our scientific founder, Professor Kenji Osafune.
-
A research group of Professor Kenji Osafune has identified a drug candidate for the treatment of autosomal dominant polycystic kidney disease (ADPKD) and published a research paper about that achievement
-
Announcement for Fund raising
-
Appointment of Representative Director
-
Selected as a J-Startup, a public-private startup support program
-
Development of a method to confirm that no undifferentiated cells remain in renal progenitor cells generated from human iPS cells
-
Rege Nephro Announces Joint Research Agreement with CiRA, Kyoto University and Mitsui Chemicals Aiming to develop exosomes as a new modality (therapeutic method)
-
Rege Nephro Announces Joint Research Agreement with CiRA, Kyoto University and AstraZeneca Research aims to produce kidney tissue from induced pluripotent stem cells
-
Notice of Series A capital increase through third-party allotment of shares
-
Notice that Katsuhisa Yamaguchi, CFO and General Manager of Finance & Administration, has been appointed as a member of the board of directors
-
Toward development of cell therapy for renal diseases using iPS cells Joint research on the development of monitoring methods for the quality and manufacturing processes of nephron progenitor cells
-
Notice of Relocation
-
Current status and future directions of clinical applications using iPS cells – focus on Japan
-
An article about Toshihiro Ishikiriyama, our president, and Kenji Osafune, our Chief Scientific Advisor , was published in serial column: Series EMBARK of K-iCAP.
-
Shunjiro Sugimoto has expired his term of office of the board director, resigned general manager of the production division and became an advisor.
-
The current status and future perspectives of iPSC technology-based regenerative medicine for kidney diseases.
-
Elucidation of mechanism of the production of erythropoietin for the development of new therapeutic agents for renal anemia
-
A review article on the development of regenerative medicines for renal diseases
-
A review article on the kidney organoids generated from iPS cells and their clinical applications
-
Notice of joint research agreement with ABI CO., LTD.
-
Notice of joint research agreement with NIKKISO CO., LTD.
-
Notice of Conclusion of Joint Research Agreement with Kirin Holdings Co., Ltd.
-
Succeeded in producing a large amount of tissue that is the basis of renal collecting duct
-
Announcement of financing and business alliance
-
Regenerate renal tissue from multiple renal progenitor cells differentiated from human iPS cells separately
-
Immobilization of low molecular weight compounds that replace BMP7 in the expansion method of renal progenitor cells
-
The company name has been changed from RegeNephron Co., Ltd. to Rege Nephro Co., Ltd.
-
Rege Nephron Co., Ltd. was established.
-
Tamibarotene Designated as an Orphan Drug for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
Rege Nephro Co., Ltd. Selected for the Incubator Program “Bayer Co.Lab Connect”
-
Rege Nephro Co., Ltd. Signs Collaborative Research Agreement with Fujifilm for the Development of a Human Kidney Chip
-
Rege Nephro Co., Ltd. Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals, Inc.
-
Rege Nephro Co., Ltd. and Roche Enter into Collaborative Research Agreement on iPSC-Derived Human Disease Models
-
Patient Enrollment for Phase II clinical trial for Tamibarotene for ADPKD has been completed
-
Rege Nephro featured as One of the Companies in “7 Japanese Startups to Watch in 2025”
-
Rege Nephro awarded as a 2024 KSII Zebra by Kansai Innovation Initiative
-
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
-
Upcoming Feature on NHK World JAPAN Science View: Freeing Patients from Dialysis! -Dr. Kenji OSAFUNE’s Challenge
-
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
-
Phase II clinical trial begins for polycystic kidney disease drug candidate identified by iPS cell-based drug discovery
-
Rege Nephro announces joint research agreement with CiRA Kyoto University and Abu Dhabi Stem Cells Center Aiming to develop new treatments for diabetes through collaborative research using iPS cells
-
Rege Nephro Announces Joint Research Agreement with CiRA-Kyoto University, Toyo Seikan Group Holdings, and Shimadzu Corporation Aiming to develop novel cell therapy that suppresses the progression of liver cirrhosis
-
Rege Nephro announces extension of joint research agreement with CiRA-Kyoto University and AstraZeneca Aiming to realize kidney regenerative medicine with a strong international team
-
Announcement for Fund raising
-
Appointment of Representative Director
-
Selected as a J-Startup, a public-private startup support program
-
Rege Nephro Announces Joint Research Agreement with CiRA, Kyoto University and Mitsui Chemicals Aiming to develop exosomes as a new modality (therapeutic method)
-
Rege Nephro Announces Joint Research Agreement with CiRA, Kyoto University and AstraZeneca Research aims to produce kidney tissue from induced pluripotent stem cells
-
Notice of joint research agreement with ABI CO., LTD.
-
Notice of joint research agreement with NIKKISO CO., LTD.
-
Notice of Conclusion of Joint Research Agreement with Kirin Holdings Co., Ltd.
